{
    "id": "dbpedia_781_0",
    "rank": 84,
    "data": {
        "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075442/",
        "read_more_link": "",
        "language": "en",
        "title": "Impact of Right Ventricular Pressure Load After Repair of Tetralogy of Fallot",
        "top_image": "https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0",
        "meta_img": "https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0",
        "images": [
            "https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png",
            "https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg",
            "https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg",
            "https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg",
            "https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/logo-jaha.gif",
            "https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/corrauth.gif",
            "https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/corrauth.gif",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075442/bin/JAH3-11-e022694-g004.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075442/bin/JAH3-11-e022694-g003.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075442/bin/JAH3-11-e022694-g002.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075442/bin/JAH3-11-e022694-g001.jpg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "Heiner Latus",
            "Jana Stammermann",
            "Inga Voges",
            "Birgit Waschulzik",
            "Matthias Gutberlet",
            "Gerhard‐Paul Diller",
            "Dietmar Schranz",
            "Peter Ewert",
            "Philipp Beerbaum",
            "Titus Kühne"
        ],
        "publish_date": "2022-04-05T00:00:00",
        "summary": "",
        "meta_description": "Right ventricular outflow tract (RVOT) stenosis after repair of tetralogy of Fallot has been linked with favorable right ventricular remodeling but adverse outcomes. The aim of our study was to assess the hemodynamic impact and prognostic relevance of ...",
        "meta_lang": "en",
        "meta_favicon": "https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.ico",
        "meta_site_name": "PubMed Central (PMC)",
        "canonical_link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075442/",
        "text": "J Am Heart Assoc. 2022 Apr 5; 11(7): e022694.\n\nPMCID: PMC9075442\n\nPMID: 35301850\n\nImpact of Right Ventricular Pressure Load After Repair of Tetralogy of Fallot\n\n, MD, 1 , MD, 2 , MD, 3 , MSc, 4 , MD, PhD, EBCR, 5 , MD, 6 , MD, 2 , MD, 1 , 7 , MD, 8 , MD, 9 , MD, 10 and the German Competence Network for Congenital Heart Defects Investigators *\n\nHeiner Latus\n\n1 Clinic for Pediatric Cardiology and Congenital Heart Disease, German Heart Centre Munich, Munich Germany\n\nFind articles by Heiner Latus\n\nJana Stammermann\n\n2 Pediatric Heart Centre, Giessen Germany\n\nFind articles by Jana Stammermann\n\nInga Voges\n\n3 Department of Congenital Heart Disease and Pediatric Cardiology, University Children’s Hospital Kiel, Kiel Germany\n\nFind articles by Inga Voges\n\nBirgit Waschulzik\n\n4 Institute for AI and Informatics in Medicine, Technical University Munich, Munich Germany\n\nFind articles by Birgit Waschulzik\n\nMatthias Gutberlet\n\n5 Department of Diagnostic and Interventional Radiology, Heart Centre Leipzig–University Leipzig, Leipzig Germany\n\nFind articles by Matthias Gutberlet\n\nGerhard‐Paul Diller\n\n6 Division of Adult Congenital and Valvular Heart Disease, Department of Cardiovascular Medicine, University Hospital of Muenster, Muenster Germany\n\nFind articles by Gerhard‐Paul Diller\n\nDietmar Schranz\n\n2 Pediatric Heart Centre, Giessen Germany\n\nFind articles by Dietmar Schranz\n\nPeter Ewert\n\n1 Clinic for Pediatric Cardiology and Congenital Heart Disease, German Heart Centre Munich, Munich Germany\n\n7 DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich Germany\n\nFind articles by Peter Ewert\n\nPhilipp Beerbaum\n\n8 Department of Pediatric Cardiology, Hannover Medical School, Hannover Germany\n\nFind articles by Philipp Beerbaum\n\nTitus Kühne\n\n9 Clinic for Pediatric Cardiology and Congenital Heart Disease, German Heart Centre Berlin, Berlin Germany\n\nFind articles by Titus Kühne\n\nSamir Sarikouch\n\n10 Department of Heart, Thoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover Germany\n\nFind articles by Samir Sarikouch\n\n1 Clinic for Pediatric Cardiology and Congenital Heart Disease, German Heart Centre Munich, Munich Germany\n\n2 Pediatric Heart Centre, Giessen Germany\n\n3 Department of Congenital Heart Disease and Pediatric Cardiology, University Children’s Hospital Kiel, Kiel Germany\n\n4 Institute for AI and Informatics in Medicine, Technical University Munich, Munich Germany\n\n5 Department of Diagnostic and Interventional Radiology, Heart Centre Leipzig–University Leipzig, Leipzig Germany\n\n6 Division of Adult Congenital and Valvular Heart Disease, Department of Cardiovascular Medicine, University Hospital of Muenster, Muenster Germany\n\n7 DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich Germany\n\n8 Department of Pediatric Cardiology, Hannover Medical School, Hannover Germany\n\n9 Clinic for Pediatric Cardiology and Congenital Heart Disease, German Heart Centre Berlin, Berlin Germany\n\n10 Department of Heart, Thoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover Germany\n\nHeiner Latus, Email: moc.liamelgoog@sutal.renieh.\n\nCorresponding author.\n\n* Correspondence to: Heiner Latus, MD, Clinic for Pediatric Cardiology and Congenital Heart Disease, German Heart Center Munich, Technical University Munich, Lazarettstrasse 36, 80636 Munich, Germany. E‐mail: moc.liamelgoog@sutal.renieh\n\n*The German Competence Network for Congenital Heart Defects Investigators are listed in the Appendix at the end of the article.\n\nCopyright © 2022 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.\n\nThis is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.\n\nAssociated Data\n\nSupplementary Materials\n\nJAH3-11-e022694-s001.pdf (357K)\n\nGUID: B3A2327A-2D3A-4068-8795-AC44C0CCF9FC\n\nAbstract\n\nBackground\n\nRight ventricular outflow tract (RVOT) stenosis after repair of tetralogy of Fallot has been linked with favorable right ventricular remodeling but adverse outcomes. The aim of our study was to assess the hemodynamic impact and prognostic relevance of right ventricular pressure load in this population.\n\nMethods and Results\n\nA total of 296 patients with repaired tetralogy of Fallot (mean age, 17.8±7.9 years) were included in a prospective cardiovascular magnetic resonance multicenter study. Myocardial strain was quantified by feature tracking technique at study entry. Follow‐up, including the need for pulmonary valve replacement, was assessed. The combined end point consisted of ventricular tachycardia and cardiac death. A higher echocardiographic RVOT peak gradient was significantly associated with smaller right ventricular volumes and less pulmonary regurgitation, but lower biventricular longitudinal strain. During a follow‐up of 10.1 (0.1–12.9) years, the primary end point was reached in 19 of 296 patients (cardiac death, n=6; sustained ventricular tachycardia, n=2; and nonsustained ventricular tachycardia, n=11). A higher RVOT gradient was associated with the combined outcome (hazard ratio [HR], 1.03; 95% CI, 1.00–1.06; P=0.026), and a cutoff gradient of ≥25 mm Hg was predictive for cardiovascular events (HR, 3.69; 95% CI, 1.47–9.27; P=0.005). In patients with pulmonary regurgitation ≥25%, a mild residual RVOT gradient (15–30 mm Hg) was not associated with a lower risk for pulmonary valve replacement.\n\nConclusions\n\nHigher RVOT gradients were associated with less pulmonary regurgitation and smaller right ventricular dimensions but were related to reduced biventricular strain and emerged as univariate predictors of adverse events. Mild residual pressure gradients did not protect from pulmonary valve replacement. These results may have implications for the indication for RVOT reintervention in this population.\n\nKeywords: magnetic resonance imaging, prognosis, right ventricular pressure overload, strain, tetralogy of Fallot\n\nSubject Categories: Magnetic Resonance Imaging (MRI), Prognosis, Mortality/Survival, Congenital Heart Disease, Valvular Heart Disease\n\nNonstandard Abbreviations and Acronyms\n\nPR\n\npulmonary regurgitation\n\nTOF\n\ntetralogy of Fallot\n\nClinical Perspective\n\nWhat Is New?\n\nIn patients after repair of tetralogy of Fallot, higher right ventricular outflow tract gradients were related to reduced biventricular strain and emerged as univariate predictors of adverse events.\n\nMild residual pressure gradients did not reduce the risk for later pulmonary valve replacement.\n\nWhat Are the Clinical Implications?\n\nOur findings may affect the timing and indication of pulmonary valve replacement procedures in patients after repair of tetralogy of Fallot.\n\nProspective studies will need to determine whether pulmonary valve replacement performed at lower levels of right ventricular pressure load will be associated with favorable outcomes.\n\nFollowing surgical repair of tetralogy of Fallot (TOF), pulmonary regurgitation (PR) frequently emerges as the predominant residual lesion causing progressive right ventricular (RV) enlargement, functional impairment, and, potentially, sudden cardiac death. 1 Surgical management of patients after TOF repair has therefore shifted toward a pulmonary valve‐sparing repair technique with the aim of preserving RV integrity. 2 Subsequently, some degree of residual pulmonary stenosis is typically accepted after repair and has been shown to have beneficial effects on the described adverse RV remodeling process by reducing PR and RV enlargement without compromising RV function. 3 , 4 , 5 Furthermore, mild residual RV outflow tract (RVOT) gradients may also postpone the need for pulmonary valve replacement (PVR). 6 , 7 In contrast, recent data from several studies demonstrated elevated RV pressure as an independent predictor for adverse outcome. 8 , 9 , 10 These apparently paradoxical findings suggest that the effect of RV pressure load on biventricular remodeling in patients with repaired TOF is not yet sufficiently characterized and that the underlying pathophysiological mechanisms that link increased RV pressures with unfavorable outcomes are unclear. Accordingly, the aim of this study was to assess the hemodynamic impact and prognostic relevance of RV pressure load in a larger cohort of patients with repaired TOF.\n\nMethods\n\nThe data that support the findings of this study are available from the corresponding author on reasonable request.\n\nStudy Population\n\nPatients with repaired TOF were enrolled in a prospective nationwide study by the German Competence Network for Congenital Heart Defects between 2003 and 2009 (Follow Up of Post‐Repair Tetralogy of Fallot; https://www.clinicaltrials.gov/; unique identifier, {\"type\":\"clinical-trial\",\"attrs\":{\"text\":\"NCT00266188\",\"term_id\":\"NCT00266188\"}}NCT00266188). This multicenter study included patients with repaired TOF, aged >8 years, from 14 German sites undergoing a standardized protocol, including the collection of demographic and clinical data (including echocardiography) and the assessment of cardiopulmonary exercise testing and cardiovascular magnetic resonance (CMR) imaging, as published. 11 , 12\n\nFor the current study, patients with cardiopulmonary exercise testing data (peak oxygen uptake and percentage predicted and peak heart rate), echocardiographic assessment of the peak systolic RVOT gradient, and a comprehensive initial CMR examination (including biventricular volumetry and quantification of pulmonary regurgitation fraction using phase‐contrast flow measurements) were considered for further analysis. These examinations were performed within a close time interval at study entrance, and the patients were then prospectively followed up until July 2018. Data on initial postrepair RVOT gradients as well as longitudinal hemodynamic changes were not assessed.\n\nAppropriate 4‐chamber and midventricular short‐axis cine loops of study entry CMR examinations were extracted from the central database of the Competence Network for Congenital Heart Defects. CMR feature tracking analysis (TomTec Imaging Systems, Unterschleissheim, Germany) of both ventricles was performed to assess peak global longitudinal, circumferential, and radial strain values, the early diastolic strain rate, and interventricular synchrony, as described previously. 13\n\nInformation on follow‐up data, including the occurrence of predefined adverse events and PVR procedures (both surgical and transcatheter valve implantation), was available through the infrastructure of the Competence Network for Congenital Heart Defects as all patients were also separately enrolled in the national registry database for congenital heart defects. These data include survival information as well as up‐to‐date medical reports obtained regularly from the physicians treating the patients. The study was approved by all ethics committees of the participating centers. Informed written consent was obtained from all patients or their caretakers.\n\nStatistical Analysis\n\nAll continuous variables were tested for normality using the D'Agostino‐Pearson omnibus test and are presented as a mean with SD or median and range. Comparisons between the patient groups with versus without adverse events were made with the Student t test, the Mann‐Whitney U test, or the Fisher exact test, as appropriate. The Pearson correlation coefficient was used to analyze simple linear relationships between different variables. Outcome analyses were based on freedom from PVR and the primary composite end point, including cardiac death, successful resuscitation, and documented episodes of ventricular tachycardia (either sustained or nonsustained) that occurred during the follow‐up time from the CMR study. The relationship between demographic, clinical, and CMR variables and outcomes was investigated by univariable and bivariable (including the peak RVOT gradient and one other significant parameter on univariable testing) Cox proportional‐hazard analysis (hazard ratio [HR] with 95% CI). To further assess the prognostic impact of residual RV pressure load, the study population was divided into 2 groups according to a cutoff RVOT gradient of <25 and ≥25 mm Hg. This threshold emerged from previous studies that assessed the relevance of residual RVOT stenosis in patients after repair of TOF. 4 , 5 , 13 The log‐rank (Mantel‐Cox) test was performed to compare the risk for PVR in subgroups with different degrees of RV pressure and/or volume overload. Analysis was performed using GraphPad (San Diego, CA) and SPSS (version 25.0; IBM Inc, Armonk, NY) statistical software packages. For all analyses, a 2‐tailed P<0.05 was used as the criterion for statistical significance.\n\nResults\n\nPatient Characteristics and CMR Data\n\nFrom the total population of 407 patients with repaired TOF enrolled in the multicenter study, 337 had a suitable data set for the intended analysis that included echocardiographic peak RVOT gradient, a comprehensive CMR analysis, and a completed cardiopulmonary exercise testing examination (Figure ). A comparison between the analysis sample and those patients excluded is displayed in Table S1.\n\nIn 301 of these 337 patients (89%), longitudinal follow‐up data were available (in 36 patients, no follow‐up data could be obtained within the national database of the registry for congenital heart disease in Germany). For the outcome analysis, another 5 patients were excluded as these patients already exhibited one of the predefined end points (nonsustained ventricular tachycardia [VT] in 3 patients and sustained VT in 2 patients) and were subsequently treated with specific antiarrhythmic drug therapy and/or received PVR. Finally, 296 patients who had a CMR study at a mean age of 17.8±7.9 years (range, 7.0–58.0 years) were included in the outcome analysis. The mean peak echocardiographic RVOT gradient was 20.7±14.9 mm Hg (median, 16 mm Hg; range, 2–83 mm Hg). For details, please see Table .\n\nTable 1\n\nParameterAll patients (N=296)\n\nPatients without event\n\n(N=277)\n\nPatients with event\n\n(N=19)\n\nDemographicsDiagnosis, n (%)Data available283 (96)265 (96)18 (95)TOF/pulmonary stenosis260 (92)243 (92)17 (94)TOF/PA23 (8)22 (8)1 (6)Age at CMR, y16.0 (7.0–58.0)16.0 (7.0–58.0)16.0 (8.0–44.0)Age at corrective surgery, y1.0 (0.1–28.0)1.0 (0.1–28.0)1.0 (0.1–19.0)Type of repair, n (%)Data available258 (87)240 (87)18 (95)Without TAP143 (55)131 (55)12 (67)TAP62 (24)58 (24)4 (22)TAP and pulmonary artery plasty53 (21)51 (21)2 (11)Time from repair, y14 (6–48)14 (6–48)15 (8–35)Follow‐up, y10.1 (0.1–12.9)10.1 (0.1–12.9)10.1 (0.6–12.9)PVR during follow‐up, n/total (%)119/292 (41)105/274 (38)14/18 (78)Clinical status and historyInitial palliation, n/total (%)67/282 (24)60/264 (24)7/18 (39)Previous PVR, n/total (%)70/296 (24)62/277 (22)8/19 (42)NYHA>class I, n/total (%)96/296 (32)86/277 (31)10/19 (52)12‐Lead ECG: QRS duration, ms147±22147±22146±26Cardiopulmonary exercise testPeak VO2 at VAT, mL/min per kg23.8±7.524.0±7.421.6±9.0Peak VO2, mL/min per kg31.1±8.431.3±8.226.4±10.7Peak heart rate, /min172 (79–204)172 (79–204)170 (89–197)EchocardiographyPeak RVOT gradient, mm Hg20.7±14.920.0±14.329.9±19.3Tricuspid valve regurgitation>moderate, n/total (%)22/211 (10)19/195 (10)3/16 (19)CMR studyRVEDVi, mL/m2 116 (67–242)115 (67–242)119 (84–224)RVESVi, mL/m2 57 (20–186)56 (20–161)66 (26–186)RVSVI, mL/m2 60±1660±1660±13RVEF, %51±951±947±12PR, %27 (0–65)27 (0–65)28 (1–54)RV mass, g/m2 33 (10–103)33 (10–103)35 (24–71)RV mass/volume ratio0.29 (0.08–0.74)0.22 (0.08–0.74)0.30 (0.16–0.66)LVEDVi, mL/m2 82 (43–195)81 (43–126)87 (60–195)LVESVi, mL/m2 34 (17–166)34 (17–91)37 (22–166)LVSVI, mL/m2 47 (23–87)47 (23–87)47 (28–68)LVEF, %58 (15–74)58 (20–74)56 (15–69)LV mass, g/m2 54 (30–127)54 (30–109)55 (33–127)LV mass/volume ratio0.69±0.180.69±0.180.69±0.20Feature tracking analysisRV‐LS, %−12.9±4.6−13.1±4.5−9.9±5.0RV‐CS, %−15.2±4.1−15.4±4.0−13.3±5.1LV‐LS, %−13.8±5.0−14.0±4.9−12.1±6.5LV‐CS, %−20.7±4.8−21.0±4.3−16.9±7.8LV‐RS, %25.3±8.825.6±8.521.2±11.4RV EDSR LS, 1/s0.67 (0.22–3.76)0.92 (0.22–3.76)0.96 (0.49–2.37)RV EDSR CS, 1/s0.93 (0.29–2.71)0.93 (0.29–2.71)0.90 (0.45–1.43)LV EDSR LS, 1/s1.08 (0.25–4.03)1.07 (0.25–4.03)1.22 (0.28–1.81)LV EDSR CS, 1/s1.49 (0.41–2.76)1.52 (0.46–2.73)1.34 (0.41–2.76)Interventricular dyssynchrony LS, ms44 (0–607)42 (0–607)26 (0–235)Interventricular dyssynchrony CS, ms46 (0–159)46 (0–159)48 (0–124)\n\nCorrelations\n\nPeak RVOT gradient was significantly associated with smaller RV volumes (r=−0.16; P=0.004) and less PR (r=−0.12; P=0.026), but lower RV (r=−0.23; P=0.0004) and left ventricular (LV) longitudinal systolic strain (r=−0.15; P=0.016), and lower early diastolic strain rate (r=−0.17 [P=0.01] and r=−0.22 [P=0.0006]; Figure ). No significant relationships were found between RVOT gradient and RV ejection fraction (RVEF), RV mass, and RV mass/volume ratio. LV dimensions and LV ejection fraction were not related to the RVOT gradient. Although not of statistical significance, a trend toward reduced exercise capacity (both peak oxygen uptake and oxygen uptake at ventilator anaerobic threshold) was observed with increasing RVOT gradients.\n\nPrognostic Relevance of RVOT Gradient\n\nDuring a median follow‐up of 10.1 (range, 0.1–12.9) years, the primary end point was reached in 19 of 296 patients, occurring at a median time of 10.1 (range, 0.6–12.9) years after the CMR study (cardiac death, n=6; sustained VT, n=2; and nonsustained VT, n=11). Using univariable Cox‐regression analysis, a higher RVOT gradient was significantly associated with the combined outcome (HR, 1.03; 95% CI, 1.01–1.06; P=0.006). Other significant predictors were New York Heart Association functional class >1, peak oxygen uptake, PVR during follow‐up, right ventricular end‐systolic volume (RVESVi), left ventricular end‐diastolic volume (LVEDVi), left ventricular end‐systolic volume (LVESVi), RV longitudinal strain, RV circumferential strain, LV circumferential strain, and LV radial strain (Table ).\n\nTable 2\n\nParameterHR95% CI P valueDiagnosis (TOF/PA vs TOF)1.100.14–8.400.93Age at CMR (y)1.040.99–1.080.11Age at corrective surgery (y)1.050.96–1.150.27Type of repair (TAP vs no TAP)0.630.23–1.710.37Time from repair (y)1.050.98–1.110.15Initial palliation (yes/no)2.220.74–6.630.15Previous PVR (yes/no)2.370.94–5.930.07PVR during follow‐up (yes/no)3.571.15–11.10.028* NYHA class >I (yes/no)3.421.34–8.730.01* QRS (ms)0.990.97–1.010.34Peak VO2 at VAT, mL/min per kg0.950.88–1.010.10Peak VO2, mL/min per kg0.920.88–0.970.004* Peak heart rate (/min)0.980.97–1.000.08RVOT gradient, mm Hg1.031.01–1.060.006* Tricuspid valve regurgitation > moderate (yes/no)1.190.32–4.410.79RVEDVi, mL/m2 1.011.00–1.030.10RVESVi, mL/m2 1.021.00–1.040.02* RVSVI, mL/m2 1.000.97–1.030.88RVEF, %0.960.92–1.010.13PR, %1.000.97–1.030.97RV mass, g/m2 1.010.98–1.040.56RV mass/volume ratio1.210.02–66.520.93LVEDVi (mL/m2)1.041.01–1.060.001* LVESVi, mL/m2 1.031.02–1.05<0.001* LVSVI, mL/m2 1.000.95–1.060.91LVEF, %0.960.91–1.000.07LV mass, g/m2 1.010.98–1.040.49LV mass/volume ratio0.470.03–9.160.62RV‐LS, %1.221.07–1.390.004* RV‐CS, %1.151.01–1.310.03* LV‐LS, %1.070.96–1.190.24LV‐CS, %1.161.06–1.270.002* LV‐RS, %0.930.87–1.000.04* RV EDSR LS (1/s)0.780.20–3.000.71RV EDSR CS (1/s)0.260.05–1.470.13LV EDSR LS (1/s)0.930.37–2.340.88LV EDSR CS (1/s)0.530.17–1.690.28Interventricular dyssynchrony LS, ms1.011.00–1.010.16Interventricular dyssynchrony CS, ms0.990.97–1.010.25\n\nA peak RVOT gradient of ≥25 mm Hg was associated with a >3‐fold increase in adverse cardiovascular events (HR, 3.69; 95% CI, 1.47–9.27; P=0.005) (Figure ).\n\nA subgroup analysis according to a peak RVOT gradient of <25 and ≥25 mm Hg and the degree of PR (<25% and ≥25%) is displayed in Figure S1. Patients with moderate PR and a peak RVOT gradient ≥25 mm Hg demonstrated significantly more adverse events than patients with moderate PR and a peak RVOT gradient <25 mm Hg (P<0.001). In patients with severe PR ≥25%, RVOT gradients >25 or <25 mm Hg led to no significant difference (P=0.38).\n\nInstead of multivariable testing that may not yield reliable results given the limited number of adverse events (“overfitting of the model”), bivariable testing was performed to elucidate the relationship between the peak RVOT and other parameters found to be significant on univariate analysis (Table ). All tested parameters remained independent predictors, except of the paired testing with RV longitudinal strain, where the RVOT gradient reached a level of significance of P=0.05.\n\nTable 3\n\nParameterHR95% CI P valueRVOT gradient, mm Hg1.031.00–1.050.025* Peak VO2 at VAT, mL/min per kg0.930.88–0.980.01* RVOT gradient, mm Hg1.031.00–1.060.016* LVEDVi, mL/m2 1.031.01–1.050.003* RVOT gradient, mm Hg1.041.00–1.060.007* LVESVi, mL/m2 1.031.02–1.05<0.001* RVOT gradient, mm Hg1.031.00–1.060.05RV‐LS, %1.171.02–1.350.023* RVOT gradient, mm Hg1.031.00–1.060.045* LV‐CS (%)1.141.04–1.240.006*\n\nA second univariable Cox proportional‐hazard analysis was performed that only considered death and sustained VT as adverse events (N=8) (Table S2). Peak RVOT gradient remained a significant predictor for adverse events (HR, 1.04; 95% CI, 1.00–1.07; P=0.046). Comparison between patients with <25 and ≥25 mm Hg RVOT gradient revealed a significant and much higher risk for patients with higher gradients (HR, 17.9; 95% CI, 2.19–146.2; P=0.007).\n\nRole of Peak RVOT Gradient in the Need for PVR\n\nData on PVR procedures during follow‐up were available in 292 of the 296 patients (definite information on PVR was not available in 4 patients). PVR was performed in 119 patients (41%) at a median of 3.0 (range, 0.1–12.3) years after the CMR examination (median follow‐up in the entire population, 8.3 years; range, 0.1–12.3 years).\n\nUsing univariable Cox‐regression analysis, a higher RVOT gradient was significantly associated with the need for PVR (HR, 1.02; 95% CI, 1.01–1.03; P=0.002). Other significant factors predictive for PVR were initial palliation, poorer New York Heart Association functional class, increased RV volumes and RV mass, PR severity, as well as lower RVEF and LV ejection fraction (Table ).\n\nTo assess the impact of a mild residual RVOT stenosis (peak RVOT gradient 15–30 mm Hg) on the need for PVR, this subgroup was compared with patients with no relevant gradient (<15 mm Hg) and a group of patients with moderate or severe RVOT gradient (>30 mm Hg) (Figure and Table S3). The groups were further separated into patients with <25% PR and a group with ≥25% PR. In patients with ≥25% PR, the need for PVR was similar between the different RVOT stenosis subgroups. Patients with <25% PR and RVOT gradients <30 mm Hg had the lowest risk for PVR (Table ).\n\nTable 4\n\nParameterHR95% CI P valueDiagnosis (TOF/PA vs TOF)0.750.40–1.390.36Age at CMR (y)0.980.96–1.010.17Age at corrective surgery (y)0.960.91–1.020.16Type of repair (TAP vs no TAP)0.610.41–0.890.01* Time from repair (y)0.990.96–1.020.40Initial palliation (yes/no)1.581.03–2.430.04* Previous PVR (yes/no)1.090.72–1.660.69NYHA class >I (yes/no)1.741.20–2.510.003* QRS (ms)1.011.00–1.020.01* Peak VO2 at VAT, mL/min per kg0.980.96–1.010.18Peak VO2, mL/min per kg0.980.96–1.000.08Peak heart rate (/min)0.990.98–1.000.02* RVOT gradient, mm Hg1.021.01–1.030.002* Tricuspid valve regurgitation>moderate (yes/no)1.310.70–2.460.41RVEDVi, mL/m2 1.011.00–1.03<0.001* RVESVi, mL/m2 1.031.02–1.03<0.001* RVSVI, mL/m2 1.021.01–1.04<0.001* RVEF, %0.960.95–0.98<0.001* PR, %1.041.03–1.05<0.001* RV mass, g/m2 1.021.01–1.04<0.001* RV mass/volume ratio0.460.08–2.790.40LVEDVi, mL/m2 1.000.99–1.010.86LVESVi, mL/m2 1.011.00–1.020.09LVSVI, mL/m2 0.980.96–1.000.06LVEF, %0.980.96–1.000.02* LV mass, g/m2 1.000.98–1.010.68LV mass/volume ratio0.700.22–2.170.53\n\nDiscussion\n\nOur study demonstrated that a higher peak RVOT gradient was associated with less PR and smaller RV volumes in patients with repaired TOF, but also negatively affected biventricular systolic and diastolic longitudinal strain at study entry, even in a relatively young study population, and emerged as a univariate predictor for adverse cardiovascular events. More important, peak RVOT pressure gradients of >25 mm Hg were associated with a >3‐fold higher risk for death and ventricular tachyarrhythmia, even in this young cohort. Although it remains unclear whether the peak RVOT gradient will come out as an independent predictor of adverse outcomes in this population, the results of our study underscore the hemodynamic and prognostic relevance of mild to moderate RV pressure load in patients with repaired TOF that may also have implications for the indication and timing of RVOT reinterventions. Furthermore, our study also showed that a mild residual RVOT gradient of 15 to 30 mm Hg did not protect from later PVR in patients with significant PR.\n\nHemodynamic Impact of RV Pressure Load\n\nPreservation of pulmonary valve competence and biventricular function are primary objectives in the long‐term surveillance of patients with repaired TOF. Mild to moderate residual RVOT gradients are usually well tolerated and are even supposed to have beneficial effects on exercise performance, RV enlargement, and function. 3 , 4 The results of our study support these results in so far as increased RVOT gradients were associated with less PR and smaller RV dimensions. 3 , 4 , 5 , 14 , 15 Other than reported in previous observations, no significant relationship was observed between exercise capacity and RV afterload. 16\n\nRemarkably, although RVEF and LV ejection fraction were not related to residual pressure load, a weak but significant inverse relationship with both RV and LV longitudinal systolic and diastolic myocardial strain/strain rate was observed. Contrary findings were published previously, showing preserved systolic RV strain values in patients with repaired TOF who presented with higher RVOT gradients. 13 The underlying reason for these divergent findings remains speculative, but differences in patient demographics, such as age, surgical techniques, and reinterventions, offer potential explanations.\n\nAlthough the reported simple linear correlations are not able to detect any causal relationships, it seems worth discussing potential mechanisms linking higher RV afterload with impaired RV performance. RV myocardial fibrosis is now recognized as an adverse marker for clinical outcomes in patients with repaired TOF. 17 Recent CMR studies assessed diffuse myocardial fibrosis and reported lower degrees of fibrosis within the RV myocardium with increasing RVOT gradients. 18 However, in a histopathological study performed at the time of PVR, Kido and colleagues found an elevated amount of RV fibrosis in patients with a higher RV/LV pressure ratio. 19 In fact, the CMR T1 mapping techniques applied cannot differentiate whether the observed expansion in extracellular matrix is caused by a “real” profibrotic process or is attributable to a “relative” increase caused by cardiomyocyte atrophy. Whether increased RV afterload induces reactive fibrotic remodeling of the myocardium in patients with repaired TOF therefore remains unclear, in particular where RV pressures are only mildly or moderately increased.\n\nAs a consequence of elevated RV pressure, compensatory myocardial hypertrophy occurs and promotes RV myocardial stiffness that potentially protects from progressive ventricular dilatation. 20 , 21 This assumption is supported by the finding that diastolic RV longitudinal strain rate was associated with higher pressure gradients in our population. Finally, as seen with RV myocardial strain values, a higher RVOT gradient was also negatively associated with LV longitudinal systolic and diastolic strain/strain rate, which highlights the importance of ventricular interactions in patients after repair of TOF. 22\n\nRV Pressure Load as a Predictor of Outcome\n\nIn addition to established clinical risk factors, our study demonstrated that elevated RVOT gradients measured any time after repair emerged as univariate predictors of cardiac death and ventricular tachyarrhythmia over a long‐term course. Several previous CMR studies in patients with repaired TOF identified risk factors for adverse cardiovascular events; however, RV pressure load has not been consistently analyzed in all of these studies, and where it has been included in the analysis, its prognostic relevance differs between studies. 8 , 23 , 24\n\nOur findings are in accordance with those of the multicenter INDICATOR (International Multicenter TOF Registry) study that revealed increased RV pressure as an independent risk factor. 8 , 25 In contrast to our population, higher RV mass as well as lower LV ejection fraction were further significant predictors. To explain the different results, several differences between the INDICATOR study and our study group seem worth considering: our cohort was substantially younger (median, 16.0 versus 24.4 years), the follow‐up, including adverse events, was prospectively assessed, nonsustained VT was considered as part of the composite end point, and correlations to initial exercise testing results were possible. Accordingly, our patients may potentially reflect a more contemporary cohort of TOF survivors with smaller RVs and less PR who may be affected by risk factors detected at an earlier stage.\n\nHowever, RV pressure was not found to be predictive for the occurrence of VT in another CMR multicenter study. 24 Nevertheless, increased RV afterload constitutes an important risk factor after repair of TOF, as recently demonstrated by Egbe and colleagues, who showed that elevated systolic RV pressure, assessed either invasively or noninvasively, was independently associated with death and heart transplantation. 10 Another study by this group further revealed that combined indexes of RV systolic pressure and function (ie, right ventricular end‐systolic volume and RVEF) better correlated with disease severity than volumetric measures alone. This finding demonstrates the importance of linking indexes of RV afterload with that of RV performance, in particular as these variables seem to be related and hold prognostic relevance. As reported in previous studies, RV systolic strain, but not RVEF, appeared to be a significant predictor in univariable testing. 12 , 22 , 26 , 27 More important, when combined in a bivariable model, solely RV longitudinal strain but not peak RVOT gradient remained independently associated with the combined end point. It might therefore be possible that an increased RVOT gradient translates into unfavorable outcomes by its negative impact on RV deformation.\n\nIn this study, an RVOT gradient of ≥25 mm Hg was found to be associated with a >3‐fold increased risk for the combined end point in our TOF population. This cutoff appears to be in accordance with echocardiographic systolic RV pressures of >40 mm Hg that were associated with poorer outcome in other studies. 8 , 9 These findings may potentially affect the timing of PVR procedures, whereas no conclusions can be drawn on what type of RVOT gradient is acceptable at the time of repair. In clinical routine, significantly higher RVOT gradients are typically tolerated, as current guidelines recommend PVR for patients with two thirds systolic RV of systemic pressure and/or RVOT interventions with gradients >50 mm Hg. Notably, patients with primary RV pressure load showed superior recovery of RV systolic function after PVR compared with patients with isolated PR. 28 It remains unclear whether earlier RVOT intervention can ultimately result in improved outcomes and whether an “optimal” balance between RVOT stenosis and PR can be found to effectively reduce RV volume overload and preserve RV integrity without impacting long‐term outcomes. These aspects will need to be addressed in future studies. 29 , 30 , 31\n\nRole of Peak RVOT Gradient on the Need for PVR\n\nThe need for multiple RVOT reinterventions attributable to RV hemodynamic overload constitutes a significant burden for patients with repaired TOF. Although the optimal timing for PVR has yet to be determined, it is important to consider factors that delay the need for PVR surgery. 7 A previous study by van der Hulst and colleagues reported that a mild residual RVOT gradient of 15 to 30 mm Hg reduced the requirement for PVR during follow‐up compared with patients with <15– and >30–mm Hg gradients. 6 The results of our study, however, do not support these findings. In patients with ≥25% PR, freedom from PVR did not differ significantly between patients with no (<15 mm Hg), mild (15–30 mm Hg), and moderate/severe (>30 mm Hg) RVOT gradients in our population. Furthermore, the need for PVR in patients with <25% PR and an RVOT gradient >30 mm Hg was similar to that in patients with more severe PR. Although the incidence of PVR was comparable within the 2 cohorts (41% and 41.5%), differences in ages, the “era” of surgical correction, inclusion criteria, duration of follow‐up, and criteria for the decision for PVR present factors that may explain these conflicting findings.\n\nStudy Limitations\n\nThe estimation of RV afterload using the peak systolic RVOT gradient may underestimate RV pressure, considering that elevated “downstream” pulmonary vascular resistance may be present in patients with repaired TOF. 10 Its relevance seems to be overestimated in the presence of a pulmonary PR fraction >25%. 32 Nevertheless, the assessment of RVOT gradient may be a more precise and reliable method compared with measuring the tricuspid valve regurgitation velocity jet, especially in patients with only mild tricuspid valve regurgitation. Serial measurements of the RVOT gradients and PR fractions both before and after CMR examination were not assessed in this study, but could potentially provide insight into the longitudinal evolution and progression of RV pressure load and its prognostic impact. 33 Furthermore, data on changes in peak RVOT gradient and biventricular function during exercise could also add important hemodynamic information. 34\n\nThe overall low number of adverse events, and thus the lack of a multivariable outcome analysis together with the inclusion of nonsustained VT as an end point, limits the statistical power of the outcome analysis. However, even when only patients with death and sustained VT were considered in the outcome analysis, a higher RVOT gradient remained of prognostic significance. A total of 27% of patients from the original data set were excluded for lack of long‐term follow‐up data; therefore, a certain selection bias may be present (for details, see Table S1). However, the observed differences to our understanding should not have a critical effect on the results of our analysis and its drawn conclusions as the main parameters, such as age at repair, type of repair, amount of residual stenosis/regurgitation, and exercise tolerance, were not statistically significantly different. As mentioned, the inclusion of patients with Fallot‐type pulmonary atresia (although not identified as a risk factor) as well as patients with previous PVR affects the character of the study population and needs to be considered when comparing our results with those of other studies with cohorts consisting primarily of patients with a “native” RVOT. The potential risk of PVR during follow‐up needs to be considered in view of the significant higher proportion of PVR procedures in the group with an adverse outcome. It remains unclear whether these events were related (at least in some part) to the surgical procedures or may rather reflect disease severity before PVR.\n\nConclusions\n\nAlthough higher peak RVOT gradients were associated with less PR and smaller RV dimensions, an inverse relationship with reduced systolic and diastolic biventricular longitudinal strain was present. Increased RVOT gradients also emerged as univariate predictors of adverse cardiovascular events in the long‐term course. Mildly increased pressure gradients had no protective effect on later PVR procedures. These results may have implications for the indication and timing of RVOT reintervention in patients with repaired TOF. An optimal degree of pressure load, which ensures a protective effect on RV remodeling without compromising ventricular function and outcome, still needs to be determined.\n\nAppendix\n\nList of the German Competence Network for Congenital Heart Defects Investigators\n\nGunter Kerst, Majed Kanaan, Klinik für Kinderkardiologie; Corinna Lebherz, Klinik für Kardiologie, André Rüffer, Herzchirurgie für Kinder und Erwachsene mit angeborenen Herzfehlern, Universitätsklinikum Aachen; Aachen.\n\nDimitrios Gkalpakiotis, Praxis für Kinderkardiologie; Aachen.\n\nAndrea Schedifka, Praxis für Kinder‐ und Jugendmedizin, Kinderkardiologie; Ahrensfelde.\n\nGernot Buheitel, Joachim Streble, II. Klinik für Kinder und Jugendliche, Universitätsklinikum Augsburg; Augsburg.\n\nRainer Willing, Klinik für Kinder‐ und Jugendmedizin, Kinderkardiologie, Ubbo‐Emmius‐Klinik; Aurich.\n\nStephan Schubert, Kai Thorsten Laser, Karl‐Otto Dubowy Kinderherzzentrum/Zentrum für angeborene Herzfehler, Klinik für Kinderkardiologie und angeborene Herzfehler; Eugen Sandica, Kinderherzzentrum/Zentrum für angeborene Herzfehler, Klinik für Kinderherzchirurgie und angeborene Herzfehler, Herz‐ und Diabeteszentrum NRW; Bad Oeynhausen.\n\nBurkhard Trusen, Praxis Kinder‐ und Jugendmedizin, Kinderkardiologe; Bamberg.\n\nFelix Berger, Oliver Miera, Stanislav Ovroutski, Katharina Schmitt, Klinik für angeborene Herzfehler und Kinderkardiologie; Joachim Photiadis, Klinik für die Chirurgie Angeborener Herzfehler/Kinderherzchirurgie, Deutsches Herzzentrum Berlin; Berlin.\n\nFelix Berger, Bernd Opgen‐Rhein, Katja Weiss, Sabine Klaassen, Klinik für Pädiatrie mit Schwerpunkt Kardiologie, Charité ‐ Universitätsmedizin Berlin, Campus Virchow‐Klinikum; Berlin.\n\nChristoph Berns, Praxis für Kinderheilkunde, Jugendmedizin und Kinderkardiologie; Berlin.\n\nThomas Boeckel, Guido Haverkämper, Praxis für Kinder‐ und Jugendmedizin, Kinderkardiologie; Berlin.\n\nAndreas Kästner, Heike Koch, Björn Peters, Gemeinschaftspraxis für Pädiatrische Kardiologie; Berlin.\n\nFlorian Schmidt, Praxis für Kinder‐ und Jugendmedizin, Kinderkardiologie; Berlin.\n\nJens Timme, Konstanze Engel, Birgit Franzbach, Gabriela Senft, Facharztpraxis für Kinderkardiologie und Erwachsene mit angeborenem Herzfehler; Berlin.\n\nFrank Beyer, Praxis für Kinder‐ und Jugendmedizin, Kinderkardiologie; Bielefeld.\n\nKlaus Winter, Klinik für Kinder‐ und Jugendmedizin, St.‐Agnes‐Hospital; Bocholt.\n\nJohannes Breuer, Martin Schneider, Zentrum für Kinderheilkunde, Abteilung für Kinderkardiologie; Boulos Asfour, Klinik und Poliklinik für Herzchirurgie, Universitätsklinikum Bonn; Bonn.\n\nJens Bahlmann, Eberhard Griese, Kinderkardiologische Gemeinschaftspraxis; Braunschweig.\n\nTrong Phi Lê, Klinik für strukturelle und angeborene Herzfehler/ Kinderkardiologie, Klinikum Links der Weser; Bremen.\n\nJoachim Hebe, Jan‐Hendrik Nürnberg, Elektrophysiologie Bremen, Zentrum Bremen am Klinikum Links der Weser; Bremen.\n\nAnnette Magsaam, Praxis für Kinderkardiologie und Angeborene Herzfehler; Bremen.\n\nRonald Müller, Praxis für Angeborene Herzfehler/ Kinderkardiologie; Bremen.\n\nLudger Potthoff, Praxis Celler Centrum für Kinder‐ und Jugendmedizin, Kinderkardiologie; Celle.\n\nRenate Voigt, Praxis für Kinder‐ und Jugendmedizin, Kinderkardiologie; Chemnitz.\n\nTim Krüger, Kinderarzt‐Praxis Ilmenau/Coburg, Praxis für Kinder‐ und Jugendmedizin, Kinderkardiologie; Coburg.\n\nHubert Gerleve, Ulrich Kleideiter, Kinder‐ und Jugendklinik, Christophorus‐Kliniken Coesfeld; Coesfeld.\n\nDirk Schneider‐Kulla, Klinik für Pädiatrie/Kinder‐ und Jugendheilkunde, Kinderkardiologie; Jürgen Krülls‐Münch, I. Medizinische Klinik, Klinik für Kardiologie, Angiologie und internistische Intensivtherapie, Carl‐Thiem‐Klinikum Cottbus; Cottbus.\n\nThomas Menke, Kinderkardiologie, Vestische Kinder‐ und Jugendklinik Datteln; Datteln.\n\nMartin Lehn, Praxis für Kinder‐ und Jugendkardiologie und für Erwachsene mit angeborenen Herzfehlbildungen; Dortmund.\n\nAntje Heilmann, Helge Tomczak, Praxis für Kinderkardiologie, Kinderzentrum Dresden‐Friedrichstadt; Dresden.\n\nGleb Tarusinov, Klinik für Kinderkardiologie ‐ Angeborene Herzfehler; Michael Scheid, Kinderherzchirurgie und Chirurgie für angeborene Herzfehler, Herzzentrum Duisburg; Duisburg.\n\nErtan Mayatepek, Frank Pillekamp, Klinik für Allgemeine Pädiatrie, Neonatologie und Kinderkardiologie; Artur Lichtenberg, Klinik für Kardiovaskuläre Chirurgie, Universitätsklinikum Düsseldorf; Düsseldorf.\n\nChristiane Terpeluk, Praxis für Kinder‐ und Jugendmedizin, Kinderkardiologie; Ehingen.\n\nBruno Kolterer, Kinderkardiologische Schwerpunktpraxis; Erfurt.\n\nSven Dittrich, Kinderkardiologische Abteilung; Ulrike Gundlach, Medizinische Klinik 2 ‐Kardiologie und Angiologie; Robert Cesnjevar, Kinderherzchirurgische Abteilung, Universitätsklinikum Erlangen, Friedrich‐Alexander‐Universität Erlangen‐Nürnberg; Erlangen.\n\nCarsten Müntjes, Klinik für Kinderheilkunde III, Abteilung für Pädiatrische Kardiologie Universitätsklinikum Essen; Essen.\n\nGeert Morf, Praxis für Kinder‐ und Jugendmedizin und EMAH, Kinderkardiologie; Flensburg.\n\nAnoosh Esmaeili, Klinik für Kinder‐ und Jugendmedizin, Kinderkardiologie, Universitätsklinikum Frankfurt; Frankfurt.\n\nStephan Backhoff, Praxis für Kinderkardiologie/angeborene Herzerkrankungen; Frankfurt.\n\nBrigitte Stiller, Zentrum für Kinder‐ und Jugendmedizin, Klinik für Angeborene Herzfehler/Pädiatrische Kardiologie; Friedhelm Beyersdorf, Klinik für Herz‐ und Gefäßchirurgie; Johannes Kroll, Klinik für Herz‐ und Gefäßchirurgie, Sektion Kinderherzchirurgie, Universitäts‐Herzzentrum Freiburg Bad Krozingen; Freiburg.\n\nNicole Häffner, Praxis für Kinder‐ und Jugendmedizin, Kinderkardiologie; Freiburg.\n\nJannos Siaplaouras, Praxis für Kinder‐ und Jugendmedizin, Kinderkardiologie, Erwachsene mit angeborenem Herzfehler, Bluttransfusionswesen am Herz‐Jesu‐Krankenhaus; Fulda.\n\nAntje Masri‐Zada, Praxis für Kardiologie; Gera.\n\nChristian Jux, Klinik für Kinderkardiologie und angeborene Herzfehler; Andreas Böning, Hakan Akintürk, Klinik für Herz‐, Kinderherz‐ und Gefäßchirurgie, Universitätsklinikum Gießen und Marburg; Gießen.\n\nThomas Paul, Matthias Sigler, Klinik für Pädiatrische Kardiologie und Intensivmedizin mit Neonatologie und Pädiatrischer Pneumologie; Theodor Tirilomis, Klinik für Thorax‐, Herzund Gefäßchirurgie – Schwerpunkt Kinderherzchirurgie, Universitätsklinikum Göttingen; Göttingen.\n\nGabriele Schürer, Praxis für Kinder‐ und Jugendmedizin, Kinderkardiologie; Greiz.\n\nJohannes Hartmann, Schwerpunktpraxis für Kinder‐ und Jugendkardiologie; Hagen.\n\nRalph Grabitz, Uta Liebaug, Universitätsklinik und Poliklinik für Pädiatrische Kardiologie, Universitätsklinikum Halle (Saale); Halle.\n\nClaudius Rotzsch, Kinderkardiologische Praxis; Halle.\n\nRainer Kozlik‐Feldmann, Carsten Rickers, Thomas Mir, Michael Hübler, Jörg Sachweh, Kinderkardiologie/Herzchirurgie für angeborene Herzfehler, Universitäres Herz‐ und Gefäßzentrum UKE Hamburg; Hamburg.\n\nStefan Renz, Andreas Schemm, Praxis für Kinder‐ und Jugendmedizin, Kinderkardiologie und EMAH; Hamburg.\n\nBernd Friedrich, Otmar Schlobohm, Kinder‐ und Jugendarztpraxis, Kinderkardiologie; Hamburg.\n\nDietmar Böthig, Burkhard Wermter, Andrea Kelter‐Klöpping, Klinik für Pädiatrische Kardiologie und Intensivmedizin; Alexander Horke, Chirurgie angeborener Herzfehler; Johann Bauersachs, Mechthild Westhoff‐Bleck, Klinik für Kardiologie und Angiologie, Medizinische Hochschule Hannover; Hannover.\n\nMatthias Gorenflo, Zentrum für Kinder‐ und Jugendmedizin Pädiatrische Kardiologie/Angeborene Herzfehler, Matthias Karck, Tsvetomir Loukanov, Klinik für Herzchirurgie, Universitätsklinikum Heidelberg; Heidelberg.\n\nHermann Schrüfer, Praxis für Kinder‐ und Jugendmedizin, Kinderkardiologie; Hettstadt.\n\nMartin Wilken, Kinderarzt‐Praxis Hof/Nail; Praxis für Kinder‐ und Jugendmedizin, Kinderkardiologie; Hof.\n\nHashim Abdul‐Khaliq, Tanja Rädle‐Hurst, Axel Rentzsch, Klinik für Pädiatrische Kardiologie; Hans‐Joachim Schäfers, Klinik für Thorax‐ und Herz‐Gefäß‐Chirurgie, Universitätsklinikum des Saarlandes; Homburg.\n\nHagen Reichert, Praxis für Kinder‐ und Jugendmedizin, Kinderkardiologie; Reisemedizin, Gelbfieberimpfstelle; Homburg.\n\nDaniel Vilser, Klinik für Kinder‐ und Jugendmedizin, Sektion Kardiologie, Universitätsklinikum Jena; Jena.\n\nThomas Kriebel, Klinik für Kinder‐ und Jugendmedizin, Kinderkardiologie, Westpfalz‐Klinikum; Kaiserslautern.\n\nArnulf Boysen, Schwerpunktpraxis für angeborene Herzfehler; Karlsruhe.\n\nAnselm Uebing, Inga Voges, Klinik für angeborene Herzfehler und Kinderkardiologie; Tim Attmann, Joachim Thomas Cremer, Jens Scheewe, Klinik für Herz‐ und Gefäßchirurgie, Universitätsklinikum Schleswig‐Holstein; Kiel.\n\nRegina Buchholz‐Berdau, Peter Möller, Gemeinschaftspraxis der Kinder‐ und Jugendärzte und Kinderkardiologen; Kiel.\n\nThorsten Horter, Schwerpunktpraxis für Kinder‐ und Jugendkardiologie; Kiel.\n\nKonrad Brockmeier, Klinik und Poliklinik für Kinderkardiologie, Gerardus B. W. EBennink, Klinik für Herz‐ und Thoraxchirurgie, Schwerpunkt Kinderherzchirurgie, Stephan Baldus, Klinik III für Innere Medizin, Herzzentrum Universitätsklinikum Köln; Köln.\n\nAlex Gillor, Praxis für Kinder‐ und Jugendkardiologie; Köln.\n\nTim Niehues, Wolfgang Lawrenz, Zentrum für Kinder‐ und Jugendmedizin, Kinderkardiologie, HELIOS Klinikum Krefeld; Krefeld.\n\nSteffen Leidig, Praxis für Kinder‐ und Jugendmedizin, Kinderkardiologie; Lauf.\n\nIngo Dähnert, Frank‐Thomas Riede, Universitätsklinik für Kinderkardiologie; Martin Kostelka, Universitätsklinik für Herzchirurgie, Kinderherzchirurgie, Herzzentrum Leipzig; Leipzig.\n\nLiane Kändler, Medizinisches Versorgungszentrum Jessen, Außenstelle Wittenberg und Klinik für Kinder‐ und Jugendmedizin, Paul Gerhardt Diakonie und Pflege GmbH; Lutherstadt Wittenberg.\n\nMartin Bethge, Stefan Köster, Praxis für Kinder‐ und Jugendmedizin, Kinderkardiologie und EMAH; Lübeck.\n\nChristoph Schröder, Praxis für Kinderkardiologie, Kinderpneumologie, Erwachsene mit angeborenen Herzfehlern; Lüneburg.\n\nJens Karstedt, Kardiologische Schwerpunkpraxis für Kinder und Jugendliche am Klinikum Magdeburg; Magdeburg.\n\nUwe Seitz, Praxis für Kinder‐ Jugendmedizin, Kinderkardiologie; Maintal.\n\nChristoph Kampmann, Zentrum für Kinder‐ und Jugendmedizin, Abteilung für Kinderkardiologie, Daniel‐Sebastian Dohle, Klinik und Poliklinik für Herz‐, Thorax‐ und Gefäßchirurgie, Universitätsmedizin der Johannes Gutenberg‐Universität Mainz; Mainz.\n\nFrank Stahl, Praxis für Kinder‐ und Jugendkardiologie, arterielle Hypertonie bei Kindern und Jugendlichen, Erwachsene mit angeborenen Herzfehlern; Mannheim.\n\nMojtaba Abedini, Praxis für Kinder‐ und Jugendkardiologie am Universitätsklinikum Gießen und Marburg; Marburg.\n\nJoachim Müller‐Scholden, Praxis für Kinder‐ und Jugendmedizin, Kinderkardiologie; Marktheidenfeld.\n\nPeter Ewert, Alfred Hager, Michael Huntgeburth, Harald Kaemmerer, Nicole Nagdyman, Jörg Schoetzau, Oktay Tutarel, Klinik für Kinderkardiologie und Angeborene Herzfehler; Rüdiger Lange, Klinik für Herz‐ und Gefäßchirurgie; Jürgen Hörer, Klinik für Chirurgie angeborener Herzfehler und Kinderherzchirurgie Deutsches Herzzentrum München; München.\n\nNikolaus AHaas, Abteilung Kinderkardiologie und Pädiatrische Intensivmedizin; Jürgen Hörer, Herzchirurgische Klinik und Poliklinik, Sektion Kinderherzchirurgie; Klinikum der Ludwig‐Maximilians‐Universität, Campus Großhadern; München.\n\nMichael Hauser, Praxis für Kinder‐ und Jugendkardiologie und Erwachsene mit angeborenen Herzfehlern; München.\n\nAlexander Roithmaier, Praxis für Kinder‐ und Jugendmedizin, Schwerpunktpraxis für Kinderund Jugendkardiologie; München.\n\nHans‐Gerd Kehl, Astrid Lammers, Klinik für Kinder‐ und Jugendmedizin – Pädiatrische Kardiologie, Edward Malec, Department für Herz‐ und Thoraxchirurgie, Abteilung Kinderherzchirurgie; Helmut Baumgartner, Gerhard Diller, Klinik und Poliklinik für Erwachsene mit angeborenen (EMAH) und erworbenen Herzfehlern, Universitätsklinikum Münster; Münster.\n\nRoswitha Bahle, Praxis für Kinder‐ und Jugendmedizin, Kinderkardiologie; Neubrandenburg.\n\nGerald Hofner, Praxis für Kinder‐ und Jugendmedizin, Kinderkardiologie; Neudrossenfeld.\n\nStefan Zink, Praxis für Kinder‐ und Jugendmedizin, Kinderkardiologie; Nürnberg.\n\nRoland Reif, Helmut Singer; Gemeinschaftspraxis für Kinder‐ und Jugendmedizin, Kinderkardiologie, Allergologie, Asthmatraining, Psychotherapie; Nürnberg.\n\nChristoph Parlasca, Klinik für Kinder‐ und Jugendmedizin, Evangelisches Krankenhaus Oberhausen; Oberhausen.\n\nMatthias WFreund, Michael Schumacher, Universitätsklinik für Kinder‐ und Jugendmedizin, Klinik für Neonatologie, Intensivmedizin und Kinderkardiologie, Klinikum Oldenburg ‐Elisabeth‐Kinderkrankenhaus; Oldenburg.\n\nOliver Dewald, Universitätsklinik für Herzchirurgie, Klinikum Oldenburg; Oldenburg.\n\nChristine Darrelmann, Gemeinschaftspraxis für Kinder‐ und Jugendmedizin, Kinderkardiologie; Oldenburg.\n\nOlaf Willmann, Praxis für Kinder‐ und Jugendmedizin, Kinderkardiologie; Osnabrück.\n\nNorbert Schmiedl, Praxis für Kinderkardiologie; Passau.\n\nPeter Quick, Praxis für Kinder‐ und Jugendmedizin, Kinderkardiologie; Plauen.\n\nDirk Hillebrand, Praxis für Kinder‐ und Jugendmedizin, Schwerpunktpraxis Kinderkardiologie, Angeborene Herzfehler; Pinneberg.\n\nStephan Michele Eiselt, Praxis für Kinder‐ und Jugendmedizin, Kinderkardiologie und EMAH; Reinbek.\n\nTorsten Nekarda, Klinik für Kinder‐ und Jugendmedizin, Agaplesion Diakonieklinikum Rotenburg; Rotenburg.\n\nMichael Eberhard, Praxis für Kinder‐ und Jugendmedizin, Kinderkardiologie; Rottweil.\n\nGeorg Baier, Praxis für Kinder‐ und Jugendmedizin, Kinderkardiologie; Schwabach.\n\nFrank Uhlemann, Zentrum für angeborene Herzfehler, Olgahospital; Stuttgart.\n\nIoannis Tzanavaros, Chirurgie für angeborene Herzfehler/Kinderherzchirurgie, Sana Herzchirurgie Stuttgart; Stuttgart.\n\nAlexander Beyer, Gudrun Binz, Steffen Hess, Thomas Teufel, Kinderkardiologische Praxis Stuttgart/EMAH‐Schwerpunktpraxis; Stuttgart.\n\nRonald‐Peter Handke, Praxis für Kinder‐ und Jugendmedizin, Kinderkardiologie; Trier.\n\nMichael Hofbeck, Renate Kaulitz, Ludger Sieverding, Kinderheilkunde II ‐ Kinderkardiologie, Intensivmedizin und Pulmologie; Christian Schlensak, Thorax‐, Herz‐ und Gefäßchirurgie, Migdat Mustafi, Sektion Chirurgie angeborener Herzfehler – Kinderherzchirurgie, Universitätsklinikum Tübingen; Tübingen.\n\nChristian Apitz, Michael Kaestner, Klinik für Kinder‐ und Jugendmedizin, Sektion Pädiatrische Kardiologie, Universitätsklinikum Ulm; Ulm.\n\nJürgen Holtvogt, Klinik für Kinder‐ und Jugendmedizin, Kinderkardiologie, St. Marienhospital Vechta; Vechta.\n\nCarl‐Friedrich Wippermann, Praxis für Kinder‐ und Jugendmedizin, Kinderkardiologie; Walluf.\n\nSönke Hinz, Praxis für Kinder‐ und Jugendmedizin, Kinderkardiologie; Weyhe.\n\nAndreas Heusch, Zentrum für Kinder‐ und Jugendmedizin, Abteilung Kinderkardiologie und ‐pneumologie, HELIOS Klinikum Wuppertal; Wuppertal.\n\nJohannes Wirbelauer, Kinderklinik, Kinderkardiologie/ EMAH, Universitätsklinikum Würzburg; Würzburg.\n\nWolfgang Brosi, Praxis für Kinder‐ und Jugendmedizin, Kinderkardiologie und –pneumologie, Allergologie, Umweltmedizin, Asthma‐, Neurodermitis‐ und Anaphylaxietrainer; Würzburg.\n\nSources of Funding\n\nThe study was supported by the Doris‐Haag Stiftung, Frankfurt am Main, Germany and the Willy‐Robert‐Pitzer Stiftung, Frankfurt am Main, Germany. This work was further supported by the Competence Network for Congenital Heart Defects, funded by the Federal Ministry of Education and Research (FKZ 01G10210 for first funding period; FKZ 01GI0601 for second and third funding periods).\n\nDisclosures\n\nNone.\n\nSupporting information\n\nTables S1–S3\n\nFigure S1\n\nNotes\n\nFor Sources of Funding and Disclosures, see page 15.\n\nContributor Information\n\nthe German Competence Network for Congenital Heart Defects Investigators:\n\nReferences\n\n1. Davlouros PA, Kilner PJ, Hornung TS, Li W, Francis JM, Moon JC, Smith GC, Tat T, Pennell DJ, Gatzoulis MA. Right ventricular function in adults with repaired tetralogy of Fallot assessed with cardiovascular magnetic resonance imaging: detrimental role of right ventricular outflow aneurysms or akinesia and adverse right‐to‐left ventricular interaction. J Am Coll Cardiol. 2002;40:2044–2052. doi: 10.1016/S0735-1097(02)02566-4 [PubMed] [CrossRef] [Google Scholar]\n\n2. Boni L, García E, Galletti L, Pérez A, Herrera D, Ramos V, Marianeschi SM, Comas JV. Current strategies in tetralogy of Fallot repair: pulmonary valve sparing and evolution of right ventricle/left ventricle pressures ratio. Eur J Cardio‐Thorac Surg. 2009;35:885–889; discussion 889‐890. doi: 10.1016/j.ejcts.2009.01.016 [PubMed] [CrossRef] [Google Scholar]\n\n3. Spiewak M, Biernacka EK, Małek LA, Petryka J, Kowalski M, Miłosz B, Zabicka M, Miśko J, Rużyłło W. Right ventricular outflow tract obstruction as a confounding factor in the assessment of the impact of pulmonary regurgitation on the right ventricular size and function in patients after repair of tetralogy of Fallot. J Magn Reson Imaging: JMRI. 2011;33:1040–1046. doi: 10.1002/jmri.22532 [PubMed] [CrossRef] [Google Scholar]\n\n4. Yoo BW, Kim JO, Kim YJ, Choi JY, Park HK, Park YH, Sul JH. Impact of pressure load caused by right ventricular outflow tract obstruction on right ventricular volume overload in patients with repaired tetralogy of Fallot. J Thorac Cardiovasc Surg. 2012;143:1299–1304. doi: 10.1016/j.jtcvs.2011.12.033 [PubMed] [CrossRef] [Google Scholar]\n\n5. Latus H, Gummel K, Rupp S, Valeske K, Akintuerk H, Jux C, Bauer J, Schranz D, Apitz C. Beneficial effects of residual right ventricular outflow tract obstruction on right ventricular volume and function in patients after repair of tetralogy of Fallot. Pediatr Cardiol. 2013;34:424–430. doi: 10.1007/s00246-012-0476-4 [PubMed] [CrossRef] [Google Scholar]\n\n6. van der Hulst AE, Hylkema MG, Vliegen HW, Delgado V, Hazekamp MG, Rijlaarsdam ME, Holman ER, Blom NA, Roest AA. Mild residual pulmonary stenosis in tetralogy of Fallot reduces risk of pulmonary valve replacement. Ann Thorac Surg. 2012;94:2077–2082. doi: 10.1016/j.athoracsur.2012.06.065 [PubMed] [CrossRef] [Google Scholar]\n\n7. Frigiola A, Hughes M, Turner M, Taylor A, Marek J, Giardini A, Hsia TY, Bull K. Physiological and phenotypic characteristics of late survivors of tetralogy of Fallot repair who are free from pulmonary valve replacement. Circulation. 2013;128:1861–1868. doi: 10.1161/CIRCULATIONAHA.113.001600 [PubMed] [CrossRef] [Google Scholar]\n\n8. Valente AM, Gauvreau K, Assenza GE, Babu‐Narayan SV, Schreier J, Gatzoulis MA, Groenink M, Inuzuka R, Kilner PJ, Koyak Z, et al. Contemporary predictors of death and sustained ventricular tachycardia in patients with repaired tetralogy of Fallot enrolled in the indicator cohort. Heart. 2014;100:247–253. doi: 10.1136/heartjnl-2013-304958 [PMC free article] [PubMed] [CrossRef] [Google Scholar]\n\n9. Shiraishi S, Takahashi M, Sugimoto A, Tsuchida M. Predictors of ventricular tachyarrhythmia occurring late after intracardiac repair of tetralogy of Fallot: combination of QRS duration change rate and tricuspid regurgitation pressure gradient. J Thorac Dis. 2017;9:5112–5119. doi: 10.21037/jtd.2017.11.53 [PMC free article] [PubMed] [CrossRef] [Google Scholar]\n\n10. Egbe AC, Taggart NW, Reddy YNV, Sufian M, Banala K, Vojjini R, Najam M, Osman K, Obokata M, Borlaug BA. Assessment and implications of right ventricular afterload in tetralogy of Fallot. Am J Cardiol. 2019;124:1780–1784. doi: 10.1016/j.amjcard.2019.08.035 [PubMed] [CrossRef] [Google Scholar]\n\n11. Sarikouch S, Boethig D, Peters B, Kropf S, Dubowy KO, Lange P, Kuehne T, Haverich A, Beerbaum P. Poorer right ventricular systolic function and exercise capacity in women after repair of tetralogy of Fallot: a sex comparison of standard deviation scores based on sex‐specific reference values in healthy control subjects. Circ Cardiovasc Imaging. 2013;6:924–933. doi: 10.1161/CIRCIMAGING.112.000195 [PubMed] [CrossRef] [Google Scholar]\n\n12. Orwat S, Diller G‐P, Kempny A, Radke R, Peters B, Kühne T, Boethig D, Gutberlet M, Dubowy K‐O, Beerbaum P, et al. Myocardial deformation parameters predict outcome in patients with repaired tetralogy of Fallot. Heart. 2016;102:209–215. doi: 10.1136/heartjnl-2015-308569 [PubMed] [CrossRef] [Google Scholar]\n\n13. Latus H, Hachmann P, Gummel K, Khalil M, Yerebakan C, Bauer J, Schranz D, Apitz C. Impact of residual right ventricular outflow tract obstruction on biventricular strain and synchrony in patients after repair of tetralogy of Fallot: a cardiac magnetic resonance feature tracking study. Eur J Cardiothorac Surg. 2015;48:83‐90. doi: 10.1055/s-0034-1394034 [PubMed] [CrossRef] [Google Scholar]\n\n14. Chen C‐A, Chen S‐Y, Wang J‐K, Tseng W‐Y, Chiu H‐H, Chang C‐I, Chiu I‐S, Chen Y‐S, Yang M‐C, Lu C‐W, et al. Ventricular geometric characteristics and functional benefit of mild right ventricular outflow tract obstruction in patients with significant pulmonary regurgitation after repair of tetralogy of Fallot. Am Heart J. 2014;167:555–561. doi: 10.1016/j.ahj.2013.12.026 [PubMed] [CrossRef] [Google Scholar]\n\n15. Kilner PJ, Balossino R, Dubini G, Babu‐Narayan SV, Taylor AM, Pennati G, Migliavacca F. Pulmonary regurgitation: the effects of varying pulmonary artery compliance, and of increased resistance proximal or distal to the compliance. Int J Cardiol. 2009;133:157–166. doi: 10.1016/j.ijcard.2008.06.078 [PubMed] [CrossRef] [Google Scholar]\n\n16. Freling HG, Willems TP, van Melle JP, van Slooten YJ, Bartelds B, Berger RM, van Veldhuisen DJ, Pieper PG. Effect of right ventricular outflow tract obstruction on right ventricular volumes and exercise capacity in patients with repaired tetralogy of Fallot. Am J Cardiol. 2014;113:719–723. doi: 10.1016/j.amjcard.2013.10.049 [PubMed] [CrossRef] [Google Scholar]\n\n17. Babu‐Narayan SV, Kilner PJ, Li W, Moon JC, Goktekin O, Davlouros PA, Khan M, Ho SY, Pennell DJ, Gatzoulis MA. Ventricular fibrosis suggested by cardiovascular magnetic resonance in adults with repaired tetralogy of Fallot and its relationship to adverse markers of clinical outcome. Circulation. 2006;113:405–413. doi: 10.1161/CIRCULATIONAHA.105.548727 [PubMed] [CrossRef] [Google Scholar]\n\n18. Chen CA, Dusenbery SM, Valente AM, Powell AJ, Geva T. Myocardial ECV fraction assessed by CMR is associated with type of hemodynamic load and arrhythmia in repaired tetralogy of Fallot. JACC Cardiovasc Imaging. 2016;9:1–10. [PubMed] [Google Scholar]\n\n19. Kido T, Ueno T, Taira M, Ozawa H, Toda K, Kuratani T, Sawa Y. Clinical predictors of right ventricular myocardial fibrosis in patients with repaired tetralogy of Fallot. Circ J. 2018;82:1149–1154. doi: 10.1253/circj.CJ-17-1088 [PubMed] [CrossRef] [Google Scholar]\n\n20. Bove T, Vandekerckhove K, Bouchez S, Wouters P, Somers P, Van Nooten G. Role of myocardial hypertrophy on acute and chronic right ventricular performance in relation to chronic volume overload in a porcine model: relevance for the surgical management of tetralogy of Fallot. J Thorac Cardiovasc Surg. 2014;147:1956–1965. doi: 10.1016/j.jtcvs.2013.10.026 [PubMed] [CrossRef] [Google Scholar]\n\n21. Gatzoulis MA, Clark AL, Cullen S, Newman CG, Redington AN. Right ventricular diastolic function 15 to 35 years after repair of tetralogy of Fallot: restrictive physiology predicts superior exercise performance. Circulation. 1995;91:1775–1781. doi: 10.1161/01.CIR.91.6.1775 [PubMed] [CrossRef] [Google Scholar]\n\n22. Diller G‐P, Kempny A, Liodakis E, Alonso‐Gonzalez R, Inuzuka R, Uebing A, Orwat S, Dimopoulos K, Swan L, Li W, et al. Left ventricular longitudinal function predicts life‐threatening ventricular arrhythmia and death in adults with repaired tetralogy of Fallot. Circulation. 2012;125:2440–2446. doi: 10.1161/CIRCULATIONAHA.111.086983 [PubMed] [CrossRef] [Google Scholar]\n\n23. Bokma JP, de Wilde KC, Vliegen HW, van Dijk AP, van Melle JP, Meijboom FJ, Zwinderman AH, Groenink M, Mulder BJM, Bouma BJ. Value of cardiovascular magnetic resonance imaging in noninvasive risk stratification in tetralogy of Fallot. JAMA Cardiol. 2017;2:678–683. doi: 10.1001/jamacardio.2016.5818 [PMC free article] [PubMed] [CrossRef] [Google Scholar]\n\n24. Beurskens NEG, Hagdorn QAJ, Gorter TM, Berger RMF, Vermeulen KM, van Melle JP, Ebels TE, Lui GK, Ceresnak SR, Chan FP, et al. Risk of cardiac tachyarrhythmia in patients with repaired tetralogy of Fallot: a multicenter cardiac MRI based study. Int J Cardiovasc Imaging. 2019;35:143–151. doi: 10.1007/s10554-018-1435-9 [PubMed] [CrossRef] [Google Scholar]\n\n25. Geva T, Mulder B, Gauvreau K, Babu‐Narayan SV, Wald RM, Hickey K, Powell AJ, Gatzoulis MA, Valente AM. Preoperative predictors of death and sustained ventricular tachycardia after pulmonary valve replacement in patients with repaired tetralogy of Fallot enrolled in the indicator cohort. Circulation. 2018;138:2106–2115. doi: 10.1161/CIRCULATIONAHA.118.034740 [PubMed] [CrossRef] [Google Scholar]\n\n26. Hagdorn QAJ, Vos JDL, Beurskens NEG, Gorter TM, Meyer SL, van Melle JP, Berger RMF, Willems TP. CMR feature tracking left ventricular strain‐rate predicts ventricular tachyarrhythmia, but not deterioration of ventricular function in patients with repaired tetralogy of Fallot. Int J Cardiol. 2019;295:1–6. doi: 10.1016/j.ijcard.2019.07.097 [PubMed] [CrossRef] [Google Scholar]\n\n27. Moon TJ, Choueiter N, Geva T, Valente AM, Gauvreau K, Harrild DM. Relation of biventricular strain and dyssynchrony in repaired tetralogy of Fallot measured by cardiac magnetic resonance to death and sustained ventricular tachycardia. Am J Cardiol. 2015;115:676–680. doi: 10.1016/j.amjcard.2014.12.024 [PubMed] [CrossRef] [Google Scholar]\n\n28. Harrild DM, Marcus E, Hasan B, Alexander ME, Powell AJ, Geva T, McElhinney DB. Impact of transcatheter pulmonary valve replacement on biventricular strain and synchrony assessed by cardiac magnetic resonance feature tracking. Circ Cardiovasc Interv. 2013;6:680–687. doi: 10.1161/CIRCINTERVENTIONS.113.000690 [PubMed] [CrossRef] [Google Scholar]\n\n29. Bokma JP, Geva T, Sleeper LA, Babu Narayan SV, Wald R, Hickey K, Jansen K, Wassall R, Lu M, Gatzoulis MA, et al. A propensity score‐adjusted analysis of clinical outcomes after pulmonary valve replacement in tetralogy of Fallot. Heart. 2018;104:738–744. doi: 10.1136/heartjnl-2017-312048 [PubMed] [CrossRef] [Google Scholar]\n\n30. Harrild DM, Berul CI, Cecchin F, Geva T, Gauvreau K, Pigula F, Walsh EP. Pulmonary valve replacement in tetralogy of Fallot: impact on survival and ventricular tachycardia. Circulation. 2009;119:445–451. doi: 10.1161/CIRCULATIONAHA.108.775221 [PMC free article] [PubMed] [CrossRef] [Google Scholar]\n\n31. Geva T. Tetralogy of Fallot repair: ready for a new paradigm. J Thorac Cardiovasc Surg. 2012;143:1305–1306. doi: 10.1016/j.jtcvs.2012.01.076 [PubMed] [CrossRef] [Google Scholar]\n\n32. Sakaki S, Murakami T, Shiraishi M, Yamamoto M. Impact of pulmonary valve regurgitation on pressure difference of pulmonary valve stenosis in patients with tetralogy of Fallot after repair. Pediatr Cardiol. 2018;39:1663–1668. doi: 10.1007/s00246-018-1947-z [PubMed] [CrossRef] [Google Scholar]\n\n33. Tan C, Soquet J, Brizard CP, d'Udekem Y. Evolution of residual and recurrent right ventricular outflow tract obstruction after tetralogy of Fallot repair. J Thorac Cardiovasc Surg. 2020;159:e275–e277. doi: 10.1016/j.jtcvs.2019.09.190 [PubMed] [CrossRef] [Google Scholar]\n\n34. Hasan BS, Lunze FI, McElhinney DB, Stantcheva E, Brown DW, Rhodes J, Chen MH. Exercise stress echocardiographic assessment of outflow tract and ventricular function in patients with an obstructed right ventricular‐to‐pulmonary artery conduit after repair of conotruncal heart defects. Am J Cardiol. 2012;110:1527–1533. doi: 10.1016/j.amjcard.2012.07.013 [PubMed] [CrossRef] [Google Scholar]\n\nArticles from Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease are provided here courtesy of Wiley"
    }
}